Exact Sciences Expands Oncodetect Validation, Unveils MRD Innovation Roadmap.
Exact Sciences Corporation (NASDAQ:EXAS) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds.
Exact Sciences Corp (EXAS)
Market is closed
Sector: Services-Medical Laboratories
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 1,772,369 | $76,725,854 | +10% | 1.15% |
| 2. | Millennium Management Israel Englander | 1,474,186 | $63,817,512 | -38% | 0.03% |
| 3. | Zevenbergen Capital Investments Nancy Zevenbergen | 1,167,964 | $50,561,162 | -16% | 1.23% |
| 4. | AQR Capital Management Cliff Asness | 1,011,766 | $43,647,553 | +71% | 0.04% |
| 5. | 37,500,000 | $34,518,750 | +8% | 1.37% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $51.35 | 19,500 | $1,001,325.00 | 1,074,191 | 2024-11-13 | Filing | |
| $37.71 | 2,500 | $94,275.00 | 60,858 | 2017-08-17 | Filing | |
| $13.84 | 10,000 | $138,400.00 | 136,379 | 2016-12-14 | Filing | |
| $18.10 | 5,000 | $90,500.00 | 121,247 | 2016-09-01 | Filing | |
| $17.93 | 3,380 | $60,613.20 | 105,927 | 2016-08-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $53.20 | 3,207 | $170,612.40 | 72,759 | 2025-06-13 | Filing | |
| $70.00 | 929 | $65,030.00 | 12,758 | 2024-10-08 | Filing | |
| $70.00 | 929 | $65,030.00 | 13,687 | 2024-09-18 | Filing | |
| $60.15 | 67 | $4,030.05 | 44,644 | 2024-05-01 | Filing | |
| $60.15 | 136 | $8,180.40 | 47,042 | 2024-05-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 27,723,546 | $1,200,152,338 | 0.08% | |
| 2. | 17,835,277 | $772,091,790 | 0.13% | |
| 3. | 17,637,674 | $763,534,908 | 0.01% | |
| 4. | 12,501,316 | $541,181,969 | 0.1% | |
| 5. | 11,920,721 | $516,047,997 | 0.01% |
News See All
11 Best Genomics Stocks to Buy According to Hedge Funds
Genomics is the study of genes and how they operate.
Exact Sciences Corporation (EXAS) Slid on Fear of Competition
Baron Funds, an investment management company, released its “Baron Discovery Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
10 High PE Stocks Insiders Are Buying
Insider buying represents one of the most reliable signals that investors and analysts use to gauge the business outlook of the company.
Exact Sciences Corporation (NASDAQ:EXAS) Q1 2025 Earnings Call Transcript
Operator: Thank you for standing by. My name is Kate, and I will be your conference operator today.
Billionaire George Soros' 10 Small-Cap Stocks with Huge Upside Potential
When a legendary investor like George Soros makes a move, Wall Street pays attention.
12 Best Diagnostics Stocks to Invest In Right Now
According to a report by Mordor Intelligence, the clinical diagnostics market has a size of $88.79 billion as of 2025.
Should You Invest in Exact Sciences Corp. (EXAS)?
Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here.
Here’s What Led Artisan Mid Cap Fund to Trim Exact Sciences Corporation (EXAS)
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here.
10 Cash-Rich Mid Cap Stocks To Buy Now
Cash flow is the money moving in and out of a business over a set period. It is important because it shows how much cash a company actually has on hand, rather than just looking at profits on paper.
Billionaire Hedge Funds
